Company intelligence / Profile preview
Human Biome Institute
Gdańsk, Pomorskie, Polandhuman-biome.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Human Biome Institute has demonstrated up to a 92% cure rate in recurrent C. difficile infections using their full-consortium gut microbiota preparations, including innovative capsule formulations. The company is advancing biosynthetic, donor-independent next-generation biotherapeutics targeting antibiotic-resistant bacteria and immune-related complications.[4][6][10]
- Therapeutic areas
- OncologyHematologyInfectious Diseases
- Modalities
- Live biotherapeutic products (LBPs)Biosynthetic microbiota consortiaMicrobiota transplants[2][4][6]
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Human Biome Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human Biome Institute.